Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder

Drug Safety

Volumn 31, Issue 4, 2008, Pages 345-354

  Bangs, Mark E ^a   Jin, Ling ^a   Zhang, Shuyu ^a   Desaiah, Durisala ^a   Allen, Albert J ^a   Read, Holly A ^a   Regev, Arie ^a   Wernicke, Joachim F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine, adverse reactions; Attention deficit hyperactivity disorder, treatment; Liver disorders, drug induced

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATOMOXETINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT; DATA BASE; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; JAUNDICE; LABORATORY DIAGNOSIS; LIVER TOXICITY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; PROPYLAMINES;

EID: 41149150186     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831040-00008     Document Type: Article

References (36)

1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Int Med 2002 Dec 17; 137 (12): 947-54
2. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9
3. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-85
4. Bymaster FP, Katner J, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in pre-frontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27 (5): 699-711
5. Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Pharmacother 2003 Jul; 4 (7): 1165-74
6. Swanson CJ, Perry KW, Koch-Krueger S, et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006; 50 (6): 755-60
7. Eli Lilly and Company. Strattera [package insert]. Indianapolis (IN): Eli Lilly and Company, 2006
8. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44 (6): 571-90
9. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatr 2002; 63 (Suppl. 12): 50-5
10. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003 Jan 15; 53 (2): 112-20
11. Bangs ME, Hazell P, Danckaerts M, et al. on behalf of the Atomoxetine ADHD/ODD Study Group. Atomoxetine for the treatment of attention-deficit/ hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008; 121 (2): e314-20
12. Gau SS, Huang YS, Soong WT, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17 (4): 447-460
13. Bangs ME, Emslie GJ, Spencer TJ, et al. on behalf of the Atomoxetine ADHD and Comorbid MDD Study Group. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007; 17 (4): 407-20
14. Kratochvil CJ, Michelson D, Newcorn JH, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007; 46 (9): 1128-37
15. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (9): 1119-27
16. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007; 41 (3): 322-30
17. Prasad S, Harpin V, Poole L, et al. on behalf of the SUNBEAM Study Group. A multi-centre, randomized, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2006; 23 (2): 379-94
18. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006; 26 (6): 648-52
19. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): e83
20. Spencer TJ, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-7
21. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-901
22. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114 (1): e1-8
23. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44 (7): 647-55
24. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65: 1941-9
25. Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148: 831-4
26. Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine induced hepatitis in a child. Clin Toxicol 2007; 45 (1): 51-5
27. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45 (8): 919-27
28. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006; 149 (1): 112-9
29. Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006; 45 (2): 149-57
30. PhRMA/FDA/AASLD. Drug-induced hepatotoxicity. US Food and Drug Administration 2000; FDA White Paper: 1-29
31. Temple RJ. Hepatotoxicity through the years: impact on the FDA [online]. Available from URL: http://www.fda.gov/cder/livertox/Presentations/im1389/ [Accessed 2008 Feb 21]
32. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46 (11): 1323-30
33. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002 Aug; 36 (2): 451-5
34. Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002 Nov; 37 (5): 592-600
35. Duh MS, Walker AM, Kronlund KH. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999 Jul; 8 (4): 275-83
36. US Food and Drug Administration. New warning for Strattera [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01335.html [Accessed 2007 Aug 3]